# NCT05809752 (NCT05809752)

> A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05809752
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Conditions: Leptomeningeal Disease; Triple Negative Breast Cancer; HER2-positive Breast Cancer
- Interventions: Dendritic Cell Vaccine
- Enrollment: 15
- Primary outcome: Maximum Tolerated Dose of Intrathecal Dendritic Cell Vaccine

## HCP commentary on NCT05809752 so far

What clinicians have said in podcasts, YouTube videos and X posts we have indexed. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05809752